These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 21372224)

  • 1. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Goldenberg DM
    Clin Cancer Res; 2011 May; 17(10):3157-69. PubMed ID: 21372224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
    Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
    Sharkey RM; McBride WJ; Cardillo TM; Govindan SV; Wang Y; Rossi EA; Chang CH; Goldenberg DM
    Clin Cancer Res; 2015 Nov; 21(22):5131-8. PubMed ID: 26106073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
    Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
    Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
    Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
    Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
    Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
    Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells.
    Chang CH; Gupta P; Michel R; Loo M; Wang Y; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2010 Aug; 9(8):2276-86. PubMed ID: 20663928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
    Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH
    Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
    Liu D; Cardillo TM; Wang Y; Rossi EA; Goldenberg DM; Chang CH
    Mol Cancer; 2014 Mar; 13():53. PubMed ID: 24606732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
    Pandey R; Gruslova A; Chiou J; Brenner AJ; Tiziani S
    Anal Chem; 2020 Jan; 92(1):1260-1267. PubMed ID: 31765123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
    Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
    J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.